Thursday, January 23, 2025

CATEGORY

Vertex

McKesson’s InspiroGene Teams with Vertex to Boost CASGEVY Distribution

Key TakeawaysInspiroGene's partnership with Vertex expands CASGEVY availability, potentially improving patient outcomes. Utilizing McKesson's robust distribution networks ensures efficient delivery of CASGEVY to...

Vertex Highlights Positive Phase 3 Data for Vanza Triple and TRIKAFTA® at Cystic Fibrosis Conference

Key TakeawaysVertex's new Vanza Triple combination shows non-inferiority to TRIKAFTA® and demonstrates further improvements in CFTR function in Phase 3 trials. Long-term data...

Assessing the Value of Suzetrigine for Acute Pain

The Institute for Clinical and Economic Review (ICER) has announced its plan to evaluate the comparative clinical effectiveness and value of suzetrigine (Vertex Pharmaceuticals)...

European Commission Approves Beta Thalassemia Treatment CASGEVY

Vertex Pharmaceuticals Incorporated has reached a significant achievement in the realm of severe sickle cell disease and beta thalassemia treatment with the European Commission...

European Approval Secured by Vertex for Cystic Fibrosis Medicine

Vertex Pharmaceuticals achieved a significant milestone in July 2023 when the European Commission granted an expanded label for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) with ivacaftor, specifically for...

Latest news